LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Cencora Inc

Gesloten

SectorGezondheidszorg

340.44 -0.73

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

339.18

Max

344.16

Belangrijke statistieken

By Trading Economics

Inkomsten

-1B

-340M

Verkoop

3.1B

84B

K/W

Sectorgemiddelde

44.065

76.798

EPS

3.84

Dividendrendement

0.64

Winstmarge

-0.406

Werknemers

47,000

EBITDA

-1.1B

150M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.54% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.64%

2.37%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.9B

68B

Vorige openingsprijs

341.17

Vorige sluitingsprijs

340.44

Nieuwssentiment

By Acuity

45%

55%

156 / 374 Rangschikking in Healthcare

Cencora Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 dec 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec 2025, 23:51 UTC

Winsten

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec 2025, 23:39 UTC

Belangrijke Marktbewegers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec 2025, 21:40 UTC

Winsten

Nike Sales Tick Up, But China Weakness Persists

18 dec 2025, 23:45 UTC

Marktinformatie

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec 2025, 23:37 UTC

Marktinformatie
Winsten

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec 2025, 22:58 UTC

Acquisities, Fusies, Overnames

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec 2025, 22:55 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:59 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 dec 2025, 21:35 UTC

Winsten

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec 2025, 21:31 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev Down 17% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q EPS 53c >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Apparel Rev $3.91B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Equipment Rev $550M >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q N Amer Rev $5.63B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Footwear Rev $7.66B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev $1.42B >NKE

Peer Vergelijking

Prijswijziging

Cencora Inc Prognose

Koersdoel

By TipRanks

14.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 392.82 USD  14.54%

Hoogste 417 USD

Laagste 361 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cencora Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Sentiment

By Acuity

156 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat